A Phase 3 interventional study of nivolumab and ipilimumab in Cancer, Hepatocellular, sponsored by Bristol-Myers Squibb. Completed at 107 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-26.
Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing nivolumab in Liver Neoplasms — 2 open to participants now, 4 under way, 1 of them phase 3. Nivolumab · Liver Neoplasms.
Among the 15 studies testing nivolumab in Liver Neoplasms, this one is the 7th largest by enrollment, is one of 3 that started in 2020, is one of 2 in phase 3, and was the 8th registered.
1,346 studies on the registry are indexed under Liver Neoplasms; 335 are open to participants now.
Browse Liver Neoplasms studies →2 of the 15 studies testing nivolumab in Liver Neoplasms are open now, in 1 country. Recruiting first, the newest first:
Shanghai Zhongshan Hospital · Sites in China
Ages 18–75
Shanghai Changzheng Hospital
Ages 18–75
By country, each count listing its studies:
Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 243 Liver Neoplasms studies recruiting now, 137 (56%) set no upper age limit and 69 (28%) stop at 75 or younger; 14 take children under 18; 34 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, nivolumab is the treatment under test here. Read study by study →
15 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 3 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 26 is below the median of 47 across 928 interventional studies indexed under Liver Neoplasms.
Median enrollment 22 across the 15 interventional studies. Of the 10 that completed or were terminated, 3 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 15 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Bristol-Myers Squibb has 9 studies filed under Liver Neoplasms — fewer than ten, so there is no comparison to draw.
1 of the studies testing nivolumab in Liver Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07919717Shanghai Zhongshan HospitalNIVO+IPI Neoadjuvant Therapy for Recurrent Resectable HCC | 2027-05-12 |
Add it to your calendar (.ics) → With an account.
Among the 15 studies testing nivolumab in Liver Neoplasms, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and tolerability of nivolumab with and without ipilimumab in combination with Trans-arterial ChemoEmbolization (TACE) to TACE alone in participants with intermediate liver cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol defined inclusion/exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TACE (Trans-arterial ChemoEmbolization)
Drug: nivolumab · Drug: ipilimumab · Procedure: TACE
Drug: nivolumab · Procedure: TACE
Procedure: TACE
Specified dose on specified days
Also known as: Opdivo, BMS-936558
Specified dose on specified days
Also known as: Yervoy
TACE (Trans-arterial ChemoEmbolization)
Number of Participants With Adverse Events
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.
Time frame: From first dose and 30 days after last dose of study therapy (up to approximately 25 months)
Number of Participants With Serious Adverse Events (SAEs)
Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose that results in death, Is life-threatening (defined as an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe) or requires inpatient hospitalization or causes prolongation of existing hospitalization, or results in persistent or significant disability/incapacity or is a congenital anomaly/birth defect or is an important medical event.
Time frame: From first dose and 30 days after last dose of study therapy (up to approximately 25 months)
Number of Participants Who Died
Number of participants who died due to any cause are summarized.
Time frame: From first dose and 100 days after last dose of study therapy (up to approximately 27 months)
Number of Participants With Adverse Events Leading to Study Drug Discontinuation
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.
Time frame: From first dose and 30 days after last dose of study therapy (up to approximately 25 months)
Number of Participants With Worst Grade (Grade 3/4) Laboratory Results
Laboratory results were graded using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 (Grade 3 =Severe, Grade 4 = Life-threatening). Highest grade measured for hemoglobin and albumin was Grade 3.
Time frame: From first dose and 30 days after last dose of study therapy (up to approximately 25 months)
Number of Participants With Laboratory Abnormalities in Specific Thyroid Tests
Blood samples were collected for specific thyroid test.
Time frame: From first dose and 30 days after last dose of study therapy (up to approximately 25 months)
Number of Participants With Clinical Laboratory Abnormalities in Specific Liver Tests
Blood samples were collected for specific liver tests.
Time frame: From first dose and 30 days after last dose of study therapy (up to approximately 25 months)
| Milestone | NIVO+IPI+TACE | NIVO+TACE | TACE |
|---|---|---|---|
| Started | 9 | 9 | 8 |
| Completed | 6 | 4 | 4 |
| Not completed | 3 | 5 | 4 |
| Withdrew: Other reason | 0 | 0 | 1 |
| Withdrew: Disease recurrence | 0 | 1 | 0 |
| Withdrew: Study drug toxicity | 1 | 0 | 0 |
| Withdrew: Disease progression | 1 | 2 | 3 |
| Withdrew: Administrative reasons by sponsor | 0 | 1 | 0 |
| Withdrew: Adverse event | 1 | 1 | 0 |
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.
| Participants | NIVO+IPI+TACE | NIVO+TACE | TACE |
|---|---|---|---|
| Number of Participants With Adverse Events | 9 | 9 | 8 |
Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose that results in death, Is life-threatening (defined as an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe) or requires inpatient hospitalization or causes prolongation of existing hospitalization, or results in persistent or significant disability/incapacity or is a congenital anomaly/birth defect or is an important medical event.
| Participants | NIVO+IPI+TACE | NIVO+TACE | TACE |
|---|---|---|---|
| Number of Participants With Serious Adverse Events (SAEs) | 7 | 6 | 2 |
Number of participants who died due to any cause are summarized.
| Participants | NIVO+IPI+TACE | NIVO+TACE | TACE |
|---|---|---|---|
| Number of Participants Who Died | 2 | 2 | 0 |
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.
| Participants | NIVO+IPI+TACE | NIVO+TACE | TACE |
|---|---|---|---|
| Number of Participants With Adverse Events Leading to Study Drug Discontinuation | 3 | 1 | 1 |
Laboratory results were graded using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 (Grade 3 =Severe, Grade 4 = Life-threatening). Highest grade measured for hemoglobin and albumin was Grade 3.
| Participants | NIVO+IPI+TACE | NIVO+TACE | TACE |
|---|---|---|---|
| Hemoglobin (Grade 3) | 1 | 0 | 2 |
| Platelet count (Grade 3) | 2 | 0 | 0 |
| Platelet Count (Grade 4) | 0 | 0 | 0 |
| Leukocytes (Grade 3) | 1 | 0 | 0 |
| Leukocytes (Grade 4) | 0 | 0 | 0 |
| Lymphocytes (Grade 3) | 2 | 2 | 3 |
| Lymphocytes (Grade 4) | 1 | 0 | 0 |
| Aspartate Aminotransferase (Grade 3) | 2 | 0 | 0 |
| Aspartate Aminotransferase (Grade 4) | 1 | 0 | 0 |
| Alanine Aminotransferase (Grade 3) | 1 | 1 | 0 |
| Alanine Aminotransferase (Grade 4) | 1 | 0 | 0 |
| Bilirubin, Total (Grade 3) | 0 | 0 | 0 |
| Bilirubin, TOTAL (Grade 4) | 1 | 0 | 0 |
| Creatinine, (Grade 3) | 0 | 1 | 0 |
| Creatinine (Grade 4) | 0 | 0 | 0 |
| Potassium, (Grade 3) | 1 | 1 | 0 |
| Potassium (Grade 4) | 0 | 0 | 0 |
| Amylase (Grade 3) | 2 | 0 | 0 |
| Amylase (Grade 4) | 0 | 0 | 0 |
| Lipase (Grade 3) | 4 | 0 | 1 |
| Lipase (Grade 4) | 0 | 0 | 0 |
| Albumin, (Grade 3) | 1 | 0 | 0 |
| Absolute Neutrophil Count (Grade 3) | 0 | 0 | 0 |
| Absolute Neutrophil Count (Grade 4) | 0 | 0 | 0 |
| Alkaline Phosphatase (Grade 3) | 0 | 0 | 0 |
| Alkaline Phosphatase (Grade 4) | 0 | 0 | 0 |
| Sodium (Grade 3) | 0 | 0 | 0 |
| Sodium (Grade 4) | 0 | 0 | 0 |
| Calcium, Total (Grade 3) | 0 | 0 | 0 |
| Calcium, Total (Grade 4) | 0 | 0 | 0 |
| Magnesium (Grade 3) | 0 | 0 | 0 |
| Magnesium (Grade 4) | 0 | 0 | 0 |
| Glucose (Grade 3) | 0 | 0 | 0 |
| Glucose (Grade 4) | 0 | 0 | 0 |
| Hypernatremia (Grade 3) | 0 | 0 | 0 |
| Hypernatremia (Grade 4) | 0 | 0 | 0 |
| Hyponatremia (Grade 3) | 0 | 0 | 0 |
| Hyponatremia (Grade 4) | 0 | 0 | 0 |
| Hyperkalemia (Grade 3) | 0 | 0 | 0 |
| Hyperkalemia (Grade 4) | 0 | 0 | 0 |
| Hypokalemia (Grade 3) | 1 | 1 | 0 |
| Hypokalemia (Grade 4) | 0 | 0 | 0 |
| Hypercalcemia (Grade 3) | 0 | 0 | 0 |
| Hypercalcemia (Grade 4) | 0 | 0 | 0 |
| Hypermagnesemia (Grade 3) | 0 | 0 | 0 |
| Hypermagnesemia (Grade 4) | 0 | 0 | 0 |
| Hypomagnesemia (Grade 3) | 0 | 0 | 0 |
| Hypomagnesemia (Grade 4) | 0 | 0 | 0 |
| Hypoglycemia (Grade 3) | 0 | 0 | 0 |
| Hypoglycemia (Grade 4) | 0 | 0 | 0 |
Blood samples were collected for specific thyroid test.
| Participants | NIVO+IPI+TACE | NIVO+TACE | TACE |
|---|---|---|---|
| TSH > ULN (Upper Limit of Normal) | 5 | 5 | 5 |
| TSH > ULN with TSH <= ULN at baseline | 5 | 4 | 3 |
| TSH > ULN with at least one FT3/FT4 test value < LLN (Lower Limit of Normal) | 3 | 1 | 3 |
| TSH > ULN with all other FT3/FT4 test values >= LLN | 5 | 4 | 4 |
| TSH > ULN with FT3/FT4 test missing | 0 | 2 | 1 |
| TSH < LLN | 3 | 1 | 0 |
| TSH < LLN with TSH >= LLN at baseline | 3 | 1 | 0 |
| TSH < LLN with at least one FT3/FT4 test value > ULN | 2 | 0 | 0 |
| With all other FT3/FT4 test values <= ULN | 3 | 0 | 0 |
| With FT3/FT4 test missing | 0 | 1 | 0 |
Blood samples were collected for specific liver tests.
| Participants | NIVO+IPI+TACE | NIVO+TACE | TACE |
|---|---|---|---|
| ALT or AST > 5 X Upper limit of Normal (ULN) | 3 | 2 | 0 |
| Alanine Transaminase (ALT) or AST > 10 X ULN | 2 | 1 | 0 |
| ALT or Aspartate Transaminase (AST) > 20 X ULN | 1 | 0 | 0 |
| Total Bilirubin > 2 X ULN | 3 | 2 | 1 |
| ALP (Alkaline Phosphatase) > 1.5 X ULN | 5 | 5 | 5 |
| Concurrent ALT OR AST Elevation > 3 X ULN with total Bilirubin > 2 X ULN within one day | 3 | 1 | 0 |
| Concurrent ALT or AST elevation > 3 X ULN with total Bilirubin > 2 X ULN within 30 days | 3 | 2 | 0 |
Collected over All-cause mortality was collected from randomization until their study completion (up to approximately 38 months). Serious and non-serious adverse events were collected from first dose to 100 days after last dose of study therapy (up to approximately 27 months).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| NIVO+IPI+TACE | 2/9 (22.2%) | 7/9 (77.8%) | 9/9 (100%) |
| NIVO+TACE | 2/9 (22.2%) | 6/9 (66.7%) | 9/9 (100%) |
| TACE | 0/8 (0%) | 2/8 (25%) | 8/8 (100%) |
| Event | NIVO+IPI+TACE | NIVO+TACE | TACE |
|---|---|---|---|
| PyrexiaGeneral disorders | 1/9 | 3/9 | 0/8 |
| Hepatic failureHepatobiliary disorders | 2/9 | 0/9 | 0/8 |
| Hepatic encephalopathyNervous system disorders | 2/9 | 0/9 | 0/8 |
| HaematemesisGastrointestinal disorders | 0/9 | 0/9 | 1/8 |
| Klebsiella bacteraemiaInfections and infestations | 0/9 | 0/9 | 1/8 |
| Abdominal pain upperGastrointestinal disorders | 0/9 | 1/9 | 0/8 |
| DiarrhoeaGastrointestinal disorders | 1/9 | 0/9 | 0/8 |
| Rectal haemorrhageGastrointestinal disorders | 0/9 | 1/9 | 0/8 |
| Non-cardiac chest painGeneral disorders | 1/9 | 0/9 | 0/8 |
| Hepatic infectionInfections and infestations | 1/9 | 0/9 | 0/8 |
| Event | NIVO+IPI+TACE | NIVO+TACE | TACE |
|---|---|---|---|
| ConstipationGastrointestinal disorders | 2/9 | 2/9 | 4/8 |
| PruritusSkin and subcutaneous tissue disorders | 3/9 | 4/9 | 2/8 |
| DiarrhoeaGastrointestinal disorders | 3/9 | 2/9 | 3/8 |
| Oedema peripheralGeneral disorders | 1/9 | 1/9 | 3/8 |
| Decreased appetiteMetabolism and nutrition disorders | 1/9 | 1/9 | 3/8 |
| RashSkin and subcutaneous tissue disorders | 2/9 | 1/9 | 3/8 |
| Abdominal painGastrointestinal disorders | 2/9 | 3/9 | 2/8 |
| PyrexiaGeneral disorders | 2/9 | 3/9 | 2/8 |
| AnaemiaBlood and lymphatic system disorders | 0/9 | 2/9 | 2/8 |
| DyspepsiaGastrointestinal disorders | 0/9 | 1/9 | 2/8 |
| Age, Continuous(years) | NIVO+IPI+TACE | NIVO+TACE | TACE | Total |
|---|---|---|---|---|
| Mean | 72.3 ± 10.28 | 62.7 ± 11.19 | 70.3 ± 8.89 | 68.3 ± 10.70 |
| Sex: Female, Male(Participants) | NIVO+IPI+TACE | NIVO+TACE | TACE | Total |
|---|---|---|---|---|
| Female | 2 | 1 | 1 | 4 |
| Male | 7 | 8 | 7 | 22 |
| Ethnicity (NIH/OMB)(Participants) | NIVO+IPI+TACE | NIVO+TACE | TACE | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 0 | 1 |
| Not Hispanic or Latino | 0 | 4 | 4 | 8 |
| Unknown or Not Reported | 9 | 4 | 4 | 17 |
| Race/Ethnicity, Customized(participants) | NIVO+IPI+TACE | NIVO+TACE | TACE | Total |
|---|---|---|---|---|
| White | 3 | 3 | 2 | 8 |
| Black or African American | 0 | 1 | 0 | 1 |
| Asian | 0 | 1 | 3 | 4 |
| Chinese | 2 | 2 | 1 | 5 |
| Japanese | 2 | 1 | 2 | 5 |
| Not Reported | 2 | 1 | 0 | 3 |
Showing the first 100 of 107 sites across 19 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2020 to primary completion in Dec 2023, 38 months.
Results were first posted in Nov 2024, 11 months after primary completion.
Of 30 phase 3 interventional studies under Liver Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 97. This study's 38 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Nivolumab · Ipilimumab